Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eisai Drug That Failed For Sepsis Could Be New Way To Treat Evolving Flu

This article was originally published in PharmAsia News

Executive Summary

An Eisai drug that failed testing for treating another disease may be able to provide a new way of treating influenza, including the new viruses, by acting on the patient instead of the virus.

You may also be interested in...



Coronavirus Update: Oxford Racing Ahead With 8,000 Vaccinated In Phase III Trial

Partnering with AstraZeneca, the Oxford team has opened up a clear lead in the race to enrol thousands of patients for late-stage safety and efficacy trials – but cannot make guarantees of when results might be ready.

Executives On The Move: Changes At Pieris, Skye Bioscience And More

New leaders in regulatory affairs and R&D at Skye Bioscience and promotions at Pieris Pharmaceuticals are among recent executive changes in the industry. Meanwhile, new directors were appointed at Summit Therapeutics, Ovid Therapeutics and Spero Therapeutics, among others.

The Next Big Thing In Gene Therapy Might Not Be Gene Therapy

Gene therapy remains attractive when data show new technologies can advance the field, but gene regulation, editing and RNA therapies are grabbing investors’ attention, panelists said at ARM’s Cell and Gene Meeting on the Mesa.

Topics

UsernamePublicRestriction

Register

SC084330

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel